Randomized Controlled Trial of a Novel Smoking Cessation Application Tailored to Individuals with Serious Mental Illness
针对严重精神疾病患者的新型戒烟应用程序的随机对照试验
基本信息
- 批准号:10318201
- 负责人:
- 金额:$ 65.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-15 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddressAdultAmericanAndroidBehavior TherapyBehavioral SciencesBiochemicalCardiovascular DiseasesCause of DeathCellular PhoneChronicClinical Practice GuidelineComprehensionCost Effectiveness AnalysisDA10DataDepressive disorderDevelopmentEducationElementsEnsureFutureGeneral PopulationHealth ExpendituresHealth PolicyIndividualInterventionLearningLife ExpectancyLongevityMeasurementMeasuresMediatingMediationMediator of activation proteinMental HealthMetabolic DiseasesMethodologyMethodsModelingNational Institute of Drug AbuseNicotine DependenceOutcomeParticipantPatientsPennsylvaniaPersonsPopulationPrevalencePublic HealthQuality-Adjusted Life YearsRandomizedRandomized Controlled TrialsRecommendationRelapseResearchRespiration DisordersSamplingSchizophreniaSiteSmokerSmokingSmoking Cessation InterventionStructureSymptomsTechnologyTestingTimeTobaccoTobacco useTrainingTreatment EfficacyTreatment outcomeUnited States Dept. of Health and Human ServicesUnited States National Institutes of HealthUniversitiesWorkarmbasebehavioral pharmacologycigarette smokeclinical practicecomorbiditycomparative efficacycostcost effectivecost effectivenesscost-effectiveness evaluationcravingdesigndisabilityefficacy testingevidence baseexperiencefeasibility researchfollow-uphealth economicshigh risk populationimprovedinnovative technologiesmHealthmobile applicationmobile computingnicotine replacementnicotine usenovelpilot trialpopulation healthprimary outcomerecruitretention ratesecondary outcomesevere mental illnesssmoking cessationsubstance use treatmenttheoriestherapy adherenceusability
项目摘要
PROJECT SUMMARY/ABSTRACT
Tobacco use remains at alarming high rates amongst individuals with serious mental illness, such as
schizophrenia spectrum, bipolar, and recurring depressive disorders. Smoking tobacco is the number one
preventable cause of death in this population, shortening the lifespan of adults with serious mental illness by
25 years and contributing to $317 billion in healthcare expenditures and indirect loss of earnings and disability
benefits. Novel and effective models to deliver wider-reaching smoking cessation interventions to individuals
with serious mental illness are highly needed and indicated as a priority for NIH. Mobile apps are a promising
method to deliver smoking cessation treatments to people with serious mental illness. Despite numerous apps
available to use for people with serious mental illness, our feasibility research has demonstrated that using
these apps presents daunting challenges for this population. Based on this work, we developed Learn to Quit,
a user-centered smoking cessation app tailored to the needs of individuals with serious mental illness. The
app’s main active ingredient is a novel behavioral treatment that has shown promise as a smoking cessation
intervention -- Acceptance and Commitment Therapy. The app provides education about the use of nicotine
replacement therapy and recommendations from US Clinical Practice Guidelines to ensure alignment with best
clinical practices. In a recent pilot randomized controlled trial (R00 DA037276), comparing Learn to Quit versus
NCI’s QuitGuide, we demonstrated: (1) high recruitment and retention rates, (2) high levels of user
engagement with Learn to Quit, (3) an effective method to conduct a large multi-site randomized controlled
trial, and (4) promising cessation outcomes. While this developmental work provides initial evidence of Learn to
Quit’s usability, feasibility, and preliminary efficacy, a large scale randomized controlled trial is needed to test
its efficacy in a representative sample of patients with serious mental illness. Therefore, the proposed study
will: (1) employ a randomized parallel arm design to compare the efficacy of Learn to Quit vs. NCI’s QuitGuide,
(2) use rigorous methods to evaluate mediators of app engagement and app efficacy, and (3) examine the
cost-effectiveness of Learn to Quit compared to a non-tailored app designed for the general population. The
study addresses a serious problem -- high smoking rates among people with serious mental illness -- and
proposes to test the efficacy of an easily-accessible smoking cessation intervention, using technology with the
potential for high population-level reach.
项目概要/摘要
患有严重精神疾病的人的烟草使用率仍然高得惊人,例如
精神分裂症谱系、双相情感障碍和复发性抑郁症。吸烟是第一位的
该人群中可预防的死亡原因,从而缩短患有严重精神疾病的成年人的寿命
25 年来,造成了 3170 亿美元的医疗保健支出以及间接收入和残疾损失
好处。新颖有效的模型可为个人提供更广泛的戒烟干预措施
患有严重精神疾病的患者非常需要,并被列为 NIH 的优先事项。移动应用程序很有前途
为患有严重精神疾病的人提供戒烟治疗的方法。尽管应用程序众多
可用于患有严重精神疾病的人,我们的可行性研究表明,使用
这些应用程序给这一人群带来了艰巨的挑战。基于这项工作,我们开发了学习戒烟,
一款以用户为中心的戒烟应用程序,专为满足严重精神疾病患者的需求而设计。这
该应用程序的主要活性成分是一种新颖的行为治疗方法,已显示出戒烟的希望
干预——接受和承诺疗法。该应用程序提供有关尼古丁使用的教育
替代疗法和美国临床实践指南的建议,以确保与最佳疗法保持一致
临床实践。在最近的一项随机对照试验 (R00 DA037276) 中,比较了“学习戒烟”与“戒烟”
NCI 的戒烟指南,我们展示了:(1) 高招募率和保留率,(2) 高水平的用户
参与学习戒烟,(3) 进行大型多地点随机对照研究的有效方法
试验,以及(4)有希望的戒烟结果。虽然这项开发工作提供了学习的初步证据
戒烟的可用性、可行性和初步疗效,需要大规模随机对照试验来检验
它在患有严重精神疾病的患者的代表性样本中的疗效。因此,拟议的研究
将:(1) 采用随机平行组设计来比较“学习戒烟”与 NCI 戒烟指南的功效,
(2) 使用严格的方法来评估应用程序参与度和应用程序功效的中介因素,以及 (3) 检查
与专为普通人群设计的非定制应用程序相比,“学习戒烟”的成本效益。这
研究解决了一个严重的问题——患有严重精神疾病的人吸烟率很高——并且
提议使用技术来测试易于获得的戒烟干预措施的有效性
高人口覆盖率的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roger Vilardaga其他文献
Roger Vilardaga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roger Vilardaga', 18)}}的其他基金
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness
提高数字疗法对患有精神疾病的吸烟者的健康公平性和人口影响
- 批准号:
10597126 - 财政年份:2022
- 资助金额:
$ 65.77万 - 项目类别:
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness
提高数字疗法对患有精神疾病的吸烟者的健康公平性和人口影响
- 批准号:
10457176 - 财政年份:2022
- 资助金额:
$ 65.77万 - 项目类别:
Randomized Controlled Trial of a Novel Smoking Cessation Application Tailored to Individuals with Serious Mental Illness
针对严重精神疾病患者的新型戒烟应用程序的随机对照试验
- 批准号:
10538646 - 财政年份:2020
- 资助金额:
$ 65.77万 - 项目类别:
Randomized Controlled Trial of a Novel Smoking Cessation Application Tailored to Individuals with Serious Mental Illness
针对严重精神疾病患者的新型戒烟应用程序的随机对照试验
- 批准号:
9885332 - 财政年份:2020
- 资助金额:
$ 65.77万 - 项目类别:
An Administrative Supplement to Increase the Recruitment Rates of R01 DA047301 a Pivotal Trial of a Novel Digital Therapeutic for Smoking Cessation in Psychiatric Populations
提高 R01 DA047301 招募率的行政补充 精神病人群戒烟新型数字疗法的关键试验
- 批准号:
10818811 - 财政年份:2020
- 资助金额:
$ 65.77万 - 项目类别:
Early-phase Studies of a Tailored Evidence-Based Smoking Cessation mHealth App for Persons Living with HIV
针对艾滋病毒感染者量身定制的循证戒烟 mHealth 应用程序的早期研究
- 批准号:
10016254 - 财政年份:2019
- 资助金额:
$ 65.77万 - 项目类别:
Innovative Smartphone Application for Quitting Smoking among Seriously Mentally III
用于戒烟的创新智能手机应用程序 III
- 批准号:
9326973 - 财政年份:2016
- 资助金额:
$ 65.77万 - 项目类别:
Innovative Smartphone Application for Quitting Smoking among Seriously Mentally I
用于认真戒烟的创新智能手机应用程序 I
- 批准号:
8677529 - 财政年份:2014
- 资助金额:
$ 65.77万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 65.77万 - 项目类别:
Research Grant














{{item.name}}会员




